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MaResearch in different topics in cardiovascular medicine is evolving rapidly. However, this is not the case for endocarditis,
despite its being the cardiovascular disease with the highest mortality and, at the same time, the entity with relatively
less scientiﬁc evidence supporting its treatment. Many problems are delaying research: it is an uncommon disease, few
multicenter registries are ongoing, ﬁnancing for research in this topic is lacking, randomization is costly, difﬁcult, and
considered unethical by some, and conclusions coming from propensity score analysis are taken as if they came from
randomized trials. In this review, we put forward the main issues in need of evidence and propose a different approach to
advance the understanding of left-sided infective endocarditis. We summarize the limited evidence available, the
questions that are pending, and how we should proceed to answer them. (J Am Coll Cardiol 2015;66:1068–76)
© 2015 by the American College of Cardiology Foundation.I n 1885, Sir William Osler wrote in his third Gusto-nian lecture on infective endocarditis (IE) that“few diseases present greater difﬁculties in the
way of diagnosis, difﬁculties which in many cases
are practically insurmountable” (1). We bet that he
did not expect his words to be applicable more than
150 years later. Several reasons can be exposed to ac-
count for this apparent lack of advance in research.
We underscore 2. First, IE is infrequent, kaleido-
scopic, and unpredictable. Clinical manifestations
involve almost all body systems, and the diagnosis re-
mains elusive in many cases. Second, research has
been incorrectly oriented, retrospective, and solely
based on registries, and evidence is lacking. In this re-
gard, not a single level A recommendation is given in
the most recent guidelines (2). More than 2 decades
ago, it was stated that “there is still as much art as sci-
ence in the care of patients with endocarditis” (3). It is
our duty to tip the balance in favor of science.
Despite undisputable improvements in its man-
agement, no other cardiovascular disease bears
poorer short-term outcome than left-sided infectivem the *Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico, V
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30%. Two steps can be considered crucial in the ﬁght
against LSIE: 1) the inclusion of antibiotics, which
decreased mortality dramatically in a disease that
until then was considered fatal; and 2) the introduc-
tion of surgery in its early management. Despite the
design of new more powerful antibiotics and ad-
vances in surgical methods, mortality has remained
steady for the last few decades.
We will review the main issues in need of evidence
and propose a different approach to advance the un-
derstanding of LSIE. We will summarize the limited
evidence available, what questions are pending, and
how we should proceed to answer them. Table 1
summarizes what is known and what is unsettled in
the different topics in the following sections. We
hope this review will spur the minds of basic and
clinical researchers in endocarditis for the sake of our
future patients.
Given the different epidemiological and clinical
proﬁle and outcome of “right-sided” IE (4) we will
focus on LSIE.alladolid, Spain; yInstituto Cardiovascular, Hospital
adrid, Spain. The authors have reported that they
ntin Fuster.
, accepted July 13, 2015.
AB BR E V I A T I O N S
AND ACRONYM S
FDG = ﬂuorodeoxyglucose
IE = infective endocarditis
LSIE = left-sided infective
endocarditis
PET-CT = positron emission
tomography–computed
tomography
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1069MANAGEMENT OF
NEUROLOGICAL COMPLICATIONS IN
ENDOCARDITIS IS FAR FROM CLEAR
Management of neurological complications has to
be improved. When neurological complications are
present, mortality rises up to 50%, clinical manage-
ment is difﬁcult, and cardiopulmonary bypass may be
deleterious; nonetheless, neurological complications
are frequently present when surgery is indicated for
other reasons, and even the appearance of them may
be a surgical indication.
Neurological complications appear in 20% to 40%
of patients with LSIE; one-half of them correspond to
ischemic stroke, 20% to cerebral hemorrhage, and
30% to other complications (transient ischemic
attack, meningitis, infectious aneurysm, brain ab-
scess). Their best predictor is delayed initiation of
antibiotic therapy (5); thus, the best preventive
measure is to initiate an appropriate antibiotic treat-
ment as soon as IE is suspected, always after blood
cultures have been obtained.
Whether neurological complications predict poor
outcome is an unsolved issue, and studies based on a
dichotomous classiﬁcation offer different results (6,7).
The key point of this question may be in recognizing
that there are gray areas. Poor outcomes associated
with relevant neurological complications (complicated
[8], moderate-severe [9], or clinical [10]) as compared
with irrelevant (uncomplicated [8], small [9], or sub-
clinical [10]) have been demonstrated.
The detection of asymptomatic cerebral lesions by
means of radiological techniques may improve diag-
nosis (11). However, their use cannot be generalized
unless it is demonstrated that new unexpected ﬁnd-
ings by these techniques effectively improve diag-
nosis, change management, and mainly improve
prognosis.
The decision to send patients with neurological
complications to surgery is challenging, but can be
summarized in 2 short questions (2). 1) Does the patient
have an indication for surgery? 2) Does the patient
have a prohibitive surgical risk? If the answers are yes
and no, surgery should be strongly considered.
UNCONTROLLED INFECTION IS
ARBITRARILY DEFINED
Frequently, antibiotic treatment is not sufﬁcient to
eradicate the infection in LSIE. This situation leads to
an uncontrolled infection, also known as “failure of
medical therapy,” which increases the risk of death
(12). Uncontrolled infection is, after heart failure, the
most frequent indication for surgery (13), and surgeryin these patients results in a worse prognosis
than when surgery is performed for other
reasons (14). Uncontrolled infection encom-
passes persisting infection, which is deﬁned as
fever and persistent positive blood cultures
after 7 to 10 days of appropriate antibiotic
treatment; infection due to resistant micro-
organisms; and locally uncontrolled infection
(abscess, false aneurysm, ﬁstula, and en-
larging vegetation) (2). In our opinion, this
time-dependent deﬁnition is arbitrary and vague. The
cut-off point is based not on the available evidence but
on clinical observations and expert opinions. This
period of a lack of response to antibiotic treatment,
although appropriate in other clinical scenarios, is
probably too long in IE, because the patients’ clinical
condition deteriorates quickly and makes surgery
more risky. It is paramount to anticipate this situation
by identifying the patients who are at risk of devel-
oping uncontrolled infection on the basis of clinical,
echocardiographic, and microbiological variables ob-
tained within the early stages of the disease. These
patients could beneﬁt from an early aggressive
approach.
There is only 1 study focused on this topic (15). We
observed that the persistence of positive blood cul-
tures 48 to 72 h after the initiation of antibiotic
treatment identiﬁed patients with poor outcome, and
we support this simple strategy to identify patients
with a high probability of developing uncontrolled
infection. Nonetheless, this ﬁnding should be vali-
dated in larger prospective series. The subsequent
step would be to test whether early surgery improves
the prognosis of those patients whose blood cultures
remain positive. In addition, other markers related to
a low probability of cure with antibiotics should be
investigated.
BEYOND NEGATIVE BLOOD CULTURES
Blood culture–negative IE is diagnosed when 3 or
more blood cultures collected over 48 h remain
negative despite prolonged incubation (>1 week).
Negative blood cultures can be found in different
clinical scenarios: 1) IE with blood cultures sterilized
by previous antibacterial treatment; 2) IE related to
fastidious microorganisms; and 3) IE due to intracel-
lular bacteria that cannot be routinely cultured in
blood. Negative blood cultures have been associated
with a delayed diagnosis and treatment and a worse
clinical outcome. However, most recent series ﬁnd
neither a delay in the diagnosis and treatment nor an
increase in complications or mortality (16). This could
be partly explained by the advance in the diagnostic
TABLE 1 Facts Supported By the Evidence Available and Questions Unsettled in the Different Topics
Topic Facts Supported By the Evidence Available Questions Unsettled
Neurological complications  High mortality (up to 50%)
 Frequent (20%–40%)
 Prevention: initiation of AB as soon as possible
 MR ﬁndings are useful for diagnosis
 Are NC related to poor outcome?
 Is the outcome different according to
severity of NC?
 Are cerebral MR ﬁndings useful for
prognosis?
Uncontrolled infection  Uncontrolled infection increases the risk of death
 Mortality is high when the indication for surgery is
uncontrolled infection
 The cut-off point of 7–10 days to deﬁne uncontrolled infection
is arbitrary
 Positive blood cultures after 2–3 days of AB treatment predict
poor outcome
 What amount of time after initiating AB
positive blood cultures should be
considered diagnostic of uncontrolled
infection?
Negative blood cultures  Different clinical scenarios explain negative blood cultures
in IE
 Are negative blood cultures associated
with poor outcome?
 What is the epidemiological and clinical
proﬁle of IE with negative microbio-
logical studies after 1 week?
Role for imaging  Echocardiography is crucial for diagnosis
 18F-FDG PET-CT identiﬁes peripheral emboli
(minor diagnostic criterion)
 18F-FDG PET-CT adds diagnostic information in patients with
inconclusive echocardiogram
 18F-FDG PET-CT has important limitations (see text)
 What is the role of 18F-FDG PET-CT in
diagnosis and outcome?
 What is the role of radiolabeled
leukocyte scintigraphy in diagnosis
and outcome?
Medical treatment  Aminoglycosides are ototoxic and nephrotoxic
 Vancomycin is an alternative to methicillin-sensitive
staphylococcal IE in patients who are allergic to beta lactams
 MIC of vancomycin $1.5 mg/ml in staphylococcal IE is
associated with poor outcome
 New antibiotics (daptomycin, ceftaroline) are useful in
staphylococcal IE
 What is the role of the newer available
antimicrobials and their combinations
against the most common gram-
positive cocci that cause most cases
of IE?
Vegetation size  Vegetation size predicts embolism
 Vegetations $3 cm bear very high risk
 Should vegetation size be used as the
only indication for surgery?
Timing of surgery  Heart failure, uncontrolled infection, and prevention of
embolism are indications for surgery
 The clinical condition of patients with mild heart failure may
deteriorate suddenly
 The risk of embolism is highest during the ﬁrst week of
antibiotics
 There is no survival beneﬁt in delaying surgery when indicated
in IE patients after ischemic strokes
 Can surgery be delayed once it has been
indicated?
Early surgery  Cardiac surgery carries signiﬁcant risk, but potential acute life-
threatening complications may occur if surgery is delayed
 Propensity score analysis is not an alternative to
randomized trials to create evidence
 Which markers identify the population
that may beneﬁt from early surgery?
 Does early surgery improve outcome in
high-risk patients?
Prophylaxis  AB prophylaxis prevent endocarditis in experimental
models
 Several procedures cause high-level bacteremia
 There has been a signiﬁcant increase in the incidence of IE
after restricting prophylaxis
 Which microorganisms are responsible
for the increase in the incidence of IE
after restricting prophylaxis?
 Is AB prophylaxis effective in prevent-
ing IE? If so, in whom, and when should
it be administered?
AB ¼ antibiotics; 18F-FDG PET-CT ¼ 18F-ﬂuorodeoxyglucose positron emission tomography–computed tomography; IE ¼ infective endocarditis; MIC ¼ minimal inhibitory
concentration; MR ¼ magnetic resonance; NC ¼ neurological complications.
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imaging techniques. Nevertheless, negative blood
cultures were found to predict both late survival and
events after surgery (periprosthetic leakage, reoper-
ation, and recurrence of infection) (17).
With the current automated blood culture, most of
fastidious microorganisms (including HACEK bacte-
ria) are isolated within 5 days, although some, such
as Propionibacterium acnes, may need a more pro-
longed incubation (18). Culture of metastatic septic
foci and fungal serum antigen assays can also obtain
the microbiological diagnosis. Diagnosis in bloodculture-negative IE due to some intracellular bacteria
can be reached by serology, excluding Tropheryma
whipplei. These techniques allow for a diagnosis in
most patients during the ﬁrst week. Consequently,
the term “blood culture-negative IE” should be
replaced by “IE with negative microbiological studies
after 1 week.” In these patients, the microbiological
diagnosis will be performed mainly after surgery by
valve cultures or molecular tests. Studies are needed
to explore the microbiological and clinical proﬁle of
patients with negative microbiological studies after
1 week.
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Echocardiography remains the technique of choice in
the assessment of LSIE (2). However, nuclear tech-
niques and 18F-ﬂuorodeoxyglucose (FDG) positron
emission tomography–computed tomography (PET-
CT) in particular are evolving as important additional
tools. The role of these techniques has not been
clearly established, and in fact, guidelines have not
addressed this topic yet.
The rationale of 18F-FDG PET-CT in LSIE is based
on increased uptake of FDG by inﬂammatory cells
located on valve leaﬂets or periprosthetic tissue (19).
Inclusion of abnormal FDG uptake on 18F-FDG PET-
CT as a major criterion for the diagnosis of pros-
thetic LSIE has been suggested (20). Certainly, the
detection of peripheral embolic infectious foci by this
technique may contribute—adding a minor Duke
criterion—to the diagnosis of LSIE. The question
arises as to whether or not 18F-FDG PET-CT should be
considered a major criterion along with echocardio-
graphic ﬁndings and positive blood cultures.
According to its high sensitivity and negative
predictive value, 18F-FDG PET-CT is well suited to
patients with suspected prosthetic LSIE and incon-
clusive echocardiographic results (21). In patients
with a negative study, the probability of prosthetic
LSIE is low, whereas in those showing an intense
18F-FDG uptake, the probability is high (21). Diag-
nostic difﬁculties remain in patients imaged in the
ﬁrst months after surgery.
This technique has many limitations. The accu-
racy to detect native valve infection is low, the
physiologic uptake of 18F-FDG in the normal
myocardium is rather unpredictable and may
hamper the analysis of 18F-FDG uptake in cardiac
valves, timing of the scan in relation to initiation of
antibiotic treatment may inﬂuence the ﬁnal result,
those patients who recently have undergone cardiac
surgery may have a false positive 18F-FDG PET-CT
due to the post-operative inﬂammatory response,
and other pathological conditions may increase 18F-
FDG uptake. Thus, more studies in different patient
populations (low-intermediate prevalence of LSIE)
are needed to validate the accuracy of 18F-FDG PET-
CT in LSIE before the establishment of deﬁnitive
recommendations.
In comparison to 18F-FDG PET-CT, radiolabeled
leukocyte scintigraphy showed lower sensitivity but
higher speciﬁcity for the detection of prosthetic valve
LSIE (21). Leukocyte scintigraphy might be appro-
priate for evaluating patients with suspected pros-
thetic LSIE in the ﬁrst trimester after cardiac surgery.MEDICAL TREATMENT IS NOT
EVIDENCE-BASED
Guidelines consider that there is good scientiﬁc evi-
dence available regarding the antibiotic treatment of
viridans streptococcal group, enterococcal, and
staphylococcal IE with the regimens recommended
(2,22). Nevertheless, the few randomized controlled
trials that have compared aminoglycoside-containing
combination treatment with monotherapy are incon-
clusive (23). In all of these comparisons, the trend
favored monotherapy without reaching statistical
signiﬁcance. There are no randomized controlled tri-
als comparing vancomycin with a combination of
vancomycin and an aminoglycoside. Given the inci-
dence of ototoxicity and nephrotoxicity with amino-
glycosides alone or combined with vancomycin, other
options should be explored.
Vancomycin is an alternative for methicillin-
sensitive staphylococcal IE in patients who are
allergic to beta lactams, but there are not randomized
trials comparing these antibiotics. A retrospective
study comparing beta-lactam and vancomycin in IE
caused by methicillin-sensitive staphylococci showed
a higher mortality with vancomycin, even if patients
were switched to beta-lactam (24). Treatment of
methicillin-sensitive staphylococcal IE is also ham-
pered by new data revealing that minimal inhibitory
concentrations of vancomycin $1.5 mg/ml are associ-
ated with a higher rate of complications and mortality
if these patients are treated with cloxacillin (25).
Mortality is also increased in methicillin-resistant
staphylococcal IE when vancomycin minimal inhibi-
tory concentrations are $1.5 mg/ml (26). In retrospec-
tive studies, high-dose daptomycin has been effective
for patients with either right or LSIE, although non-
susceptibility to daptomycin developed in 8.6% pa-
tients, all with methicillin-resistant staphylococcal IE
(27). Synergistic combinations against S. aureus with
daptomycin and beta lactams or fosfomycin can be
more effective and avoid the appearance of re-
sistances and nephrotoxicity (28). Ceftaroline, a
cephalosporin active against methicillin-sensitive and
methicillin-resistant staphylococcal IE, has been used
(29), but data from randomized trials are not available.
There is also an increasing resistance in entero-
cocci, with high level gentamycin resistance. More-
over, Enterococcus faecium often shows resistance to
penicillin and vancomycin. There is some evidence of
the combination of ampicillin plus ceftriaxone to
treat enterococcus faecalis IE (30), but the evidence is
scarce for other combinations of newer antibiotics
that are active against gram-positive cocci (2,22).
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clarify the role of the newer available antimicrobials
and their combinations against the most common
gram-positive cocci that cause most cases of IE.
SHOULD THE SIZE OF THE VEGETATION
AFFECT THE INDICATION FOR SURGERY?
The rationale for surgery in LSIE and large vegetations
is the prevention of systemic embolism. A vegetation
size $10 mm is a predictor of embolic events, and the
risk of embolization is particularly high for very large
(>15 mm) vegetations (31). For this reason, surgery
may be considered in isolated very large vegetations.
However, the evidence supporting this recommen-
dation is weak (2). Vegetation size is 1 of the reasons
for surgery in a high percentage of patients with
native LSIE (9,32). Nonetheless, the role of vegetation
size as the only indication for surgery is far from clear.
Four practical issues should be considered. First,
vegetation size can be 1 indication for surgery, but is
rarely the only indication. A European survey reported
that only 4 of 62 surgical patientswith native LSIEwere
treated surgically on the basis of vegetation size alone
(9). Second, not all vegetation sizes have the same
clinical effect. The incidence of embolic events after
the ﬁrst week of treatment in patients with LSIE and
vegetations $3 cm remains extremely high (20%) (13).
Third, although surgery may be effective in reducing
the risk of embolism, the operative risk has to be
balanced against this beneﬁt. Finally, prompt initia-
tion of antibiotic therapy is the most effective known
method to reduce embolic events.
The published data does not help in the decision-
making process for this scenario. Most studies on the
value of surgery reported on patients with conven-
tional surgical indications, and if theywere speciﬁcally
mentioned at all, few patients with large vegetations
as the only surgical criterion were included. Of note,
surgical treatment was associated with excess mor-
tality in patients with native valve LSIE and isolated
large vegetations (mean vegetation length 17  5 mm)
without any other indication for surgery (33).
A randomized controlled trial of surgery versus
conservative treatment in patients with very large
vegetations as the only surgical indication seems un-
feasible. In clinical practice, we have adopted a con-
servative policy: vegetation size as the only surgical
reason is more the exception rather than the rule.
TIMING OF SURGERY IN ACTIVE IE:
ONCE IT HAS BEEN INDICATED, WHY WAIT?
In some patients, surgery needs to be performed on
an emergency (within 24 h) or urgent (within a fewdays) basis. In others, surgery can be postponed for 1
or 2 weeks (2). The clinical question is: why should we
wait for surgery once the surgical indication has been
achieved? There are conﬂicting answers because of a
lack of controlled studies.
Heart failure, the most frequent cause for surgery,
is usually the result of valvular insufﬁciency, and it
must be performed on an emergency basis when pa-
tients are in pulmonary edema or cardiogenic shock
(2). Nevertheless, some physicians are reluctant to
recommend urgent surgery in patients with mild
heart failure and severe valvular insufﬁciency who
initially respond well to diuretic agents and vasodi-
lators (34). There is no solid evidence to support this
option. In this situation, we advocate urgent surgery
for three reasons: 1) despite adequate treatment, pa-
tients may rapidly progress to overt heart failure,
thus increasing operative mortality; 2) frequently, the
need for surgery will be determined by a combination
of several clinical indications, thus reinforcing the
idea of not delaying surgery and avoiding taking un-
necessary risks; and 3) as these patients will need
surgery sooner or later, why expose them to other
risks such as embolism?
Uncontrolled infection has been reviewed in
the section “Uncontrolled Infection Is Arbitrarily
Deﬁned.”
Considering that the risk of embolism in LSIE is
highest during the ﬁrst week of antibiotics (31), sur-
gery to prevent embolism must be performed ur-
gently. Urgent surgery in patients with native LSIE,
large vegetations, and severe valvular insufﬁciency
results in a reduced incidence of embolic complica-
tions without increasing mortality (35).
Patients with IE and cerebrovascular complications
should not be managed very differently. Recent data
show a lack of survival beneﬁt from delaying surgery
when indicated after ischemic strokes (36). Thus, af-
ter a stroke, if surgery is indicated, it should not be
delayed as long as coma and cerebral hemorrhage
have been excluded.
In summary, these data support the statement that
in LSIE, once the decision has been made to operate,
“the sooner the better.”
DOES EARLY SURGERY IMPROVE OUTCOME
IN HIGH-RISK PATIENTS?
An unsettled and particularly difﬁcult topic is
whether early surgery has a favorable effect on the
outcome of patients with LSIE and high risk markers.
Surgical indication is based on the presence of risk
factors, which make healing with antibiotics unlikely,
and on the patient’s comorbidities or complications,
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surgery carries signiﬁcant risk, but potential acute
life-threatening complications may occur if surgery is
delayed. A meta-analysis including 10 studies totaling
3,758 patients who had early surgery compared with
conventional medical treatment (37) documented
signiﬁcantly lower long-term all-cause mortality in
the early surgical cohort compared with conventional
treatment. Practical insights cannot be drawn because
the deﬁnition of early surgery was too loose (from
within 48 h to up to 60 days).
An interesting amount of evidence has been raised
by using propensity score analysis in different regis-
tries. The problem for clinicians is that it is not intu-
itive. An individual’s “propensity score” is deﬁned as
the conditional probability of a particular exposure
versus another, given the observed confounders. In
other words: this patient with endocarditis has been
operated on and has survived, but what was his or her
probability of survival if surgery had not been un-
dertaken? Remarkably, propensity score analysis uses
regression models, and the variables included are
arbitrarily elected. In fact, similar results to those
obtained by traditional regression modeling are
found with this type of sophisticated analysis (38).
Propensity score analysis is a good statistical tool but
is a double-edged sword. Results obtained with it are
accepted as if they came from randomized trials, but
they are not an alternative at all. We believe that the
increase observed in investigations using the pro-
pensity score analysis is delaying evidence-based
clinical research. It seems that research orientation
in LSIE is changing from clinicians to statisticians
(i.e., from bedside to computer).
Some experts believe that the evidence that dem-
onstrates the prominent role of early surgery in LSIE
is enough to support this strategy. Others, including
our group, believe that only randomized trials, which
must be multicentric given the low prevalence of this
disease, will give useful answers. There is 1 random-
ized trial (35) in which 76 patients with native LSIE,
severe valvular regurgitation, and vegetations >10
mm were randomized to surgery within 48 h or con-
ventional treatment. The primary endpoint, a com-
posite of in-hospital death and embolic events within
6 weeks after randomization, occurred in 3% of pa-
tients assigned to early surgery and in 23% of the
other arm (p ¼ 0.03). Although this study has limita-
tions (it was unicentric, only transthoracic echocar-
diography was necessary for inclusion, there was no
effect on mortality, it included a highly selected
population with only 11% of Staphylococcus aureus,
there was very low surgical mortality, and there was
an unknown severity of embolic events), the authorshave to be congratulated for demonstrating that a
randomized trial in this setting can be undertaken.
A randomized trial to test early surgery in LSIE
must meet several requirements, including strict
inclusion and exclusion criteria, homogeneity, and
adequate selection of variables and endpoints. Our
proposal is to include patients with LSIE in the ﬁrst
days after diagnosis has been made who have early
predictors of poor outcome (Central Illustration).
Early predictors include those available at admission
(clinical history, physical examination, electrocar-
diogram, blood analysis, and chest x-ray) and within
72 h (echocardiography and blood cultures) (7).
Aggressive microorganisms (Staphylococcus aureus),
mild heart failure, periannular complications, vege-
tation features, severe valvular regurgitation, heart
block, early prosthetic endocarditis, cerebral or sys-
temic embolism, and others could be considered.
Obviously, patients with an indication for surgery at
admission (severe heart failure, septic shock) and
those with contraindications have to be excluded, as
neither of them can be randomized. Therefore, pa-
tients to be randomized are those with LSIE, high
risk markers, and neither current indication nor
contraindication for surgery. Patients would be ran-
domized to surgery within 48 h or state-of-the-art
treatment, which includes surgery when those
criteria accepted in the guidelines are met. Finally,
only mortality should be regarded as a hard
endpoint. Secondary endpoints could include need
for new surgery, embolisms, days of hospital stay,
relapse, and reinfection.
PROPHYLAXIS HAS CHANGED BECAUSE
EXPERT OPINION HAS CHANGED
On the basis of experimental animal models showing
that antibiotics can prevent IE in vivo, administration
of antibiotics before procedures known to cause
bacteremia has been recommended to prevent IE.
However, as there is no deﬁnitive evidence-based data
that this practice is effective in humans, guidelines
restrict the use of antibiotic prophylaxis to patients
with the highest risk of developing IE and/or the
highest risk of an adverse outcome (2,22). Preliminary
reports showed that restricting antibiotic prophylaxis
was not associated with any harmful effect. However,
a longer follow-up found a signiﬁcant increase in the
incidence of IE for individuals at both high and lower
risk (39). The authors admit that these data do not
establish a causal association and that further inves-
tigation is warranted. Unfortunately, microbiological
data was not available. Thus, we cannot knowwhether
that increase is due to microbiological species covered
CENTRAL ILLUSTRATION Left-Sided Infective Endocarditis
San Román, J.A. et al. J Am Coll Cardiol. 2015; 66(9):1068–76.
Proposal of a randomized trial to test early surgery in left-sided infective endocarditis.
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1074by antibiotic prophylaxis. It is worth mentioning that
enterococcal and staphylococcal IE have increased in
the last 2 decades (40), and prophylaxis does not cover
these microorganisms. A more recent study from a
nationwide U.S. database found the following results
(41): 1) a steady increase in the incidence of IE over the
past decade in the United States; 2) an increasing
incidence of IE from 2000 to 2011 across all 4 pathogens
studied, but only in the case of Streptococcus, a sig-
niﬁcant rise in the incidence of IE since the 2007
guideline; and 3) the rates of hospitalization and valve
surgery for IE did not increase since the change in IE
prophylaxis guideline in 2007 (42). Unfortunately,
there is no information on the type of streptococci
isolated (oral or others) and the risk of the patients
involved.No prospective, randomized, placebo-controlled
study exists on antibiotic prophylaxis. Many thou-
sands of patients known to be at risk for IE would
have to be studied during dental and medical pro-
cedures to provide the power needed to reach sta-
tistical signiﬁcance. It is unlikely that a study large
enough could be funded. Thus, future prospective
randomized clinical trials should be directed to
subgroups of patients at highest risk and/or to pro-
cedures that cause a high degree of bacteremia. As
cumulative exposure to low-grade bacteremia
cannot be prevented with antibiotic prophylaxis,
efforts in antibiotic prophylaxis should focus on
procedures that cause a high degree of bacteremia.
In this area, we have more questions than answers.
Future research should address the degree of
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1075bacteremia caused by different procedures, the
magnitude of the risk of developing IE after various
procedures that cause bacteremia, the effectiveness
of antibiotic prophylaxis in humans, the procedures
that should be covered, which prophylactic antibiotic
regimens, if any, should be used, and many other
questions.
CONCLUSIONS
Evidence in LSIE is supported by small, retrospective,
heterogeneous, nonrandomized studies. In 1998, Da-
vid Durack stated that “the diagnosis andmanagement
of IE present an ideal application for the principles of
evidence based medicine. Many complex questions
and decisions arise, most of which have not been
formally asked or answered by means of controlled
clinical studies. Current practice is based upon an
extensive accumulation of uncontrolled clinical
experience, rather than upon proven principles” (43).
Unfortunately, researchers on IE, including our group,
have not followed this recommendation. No studies
designed to answer important clinical questions havebeen carried out. Instead, unicentric small registries
have been used to communicate individual experi-
ences, which can never substitute for good scientiﬁc
evidence. Some large, multicentric registries, in-
cluding ours, have provided important information.
However, we have to be aware of the limitations of this
tool (44), including selection bias, information bias,
heterogeneity in the population studied, heterogene-
ity in gathering data, heterogeneity among centers in
patients’ management, and subjectivity in interpreta-
tion of events. In other words, we cannot expect spe-
ciﬁc answers (e.g., does urgent surgery improve
outcome in patients with endocarditis?) from a regis-
try, a research tool that is not designed to address
speciﬁc questions (44). Only randomized trials will
help create evidence to support our decisions. They
can be done (35). What are we waiting for?
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